{
}
UBS upgraded Jazz Pharmaceuticals (JAZZ) from Neutral to Buy on March 7, 2025, with a one-year price target averaging $190.14, indicating a potential 36.93% upside from its recent closing price of $138.86. Institutional ownership has seen a slight decrease, yet total shares owned increased by 4.13% to 73,250K shares, reflecting a bullish sentiment with a put/call ratio of 0.70. Jazz Pharmaceuticals focuses on developing life-changing medicines in neuroscience and oncology, serving patients in over 90 countries.
Flutter Entertainment operates in sports betting and gaming across four segments: UK & Ireland, Australia, International, and the US. Analysts have given the stock a "buy" rating, with target prices ranging from $300 to $340, indicating potential upside. Recent trading saw shares drop to $261.94, with institutional investors significantly increasing their stakes.
Jazz Pharmaceuticals has been upgraded to a Buy rating from Neutral by UBS, indicating a positive shift in the firm's outlook on the company's stock. This upgrade reflects confidence in Jazz Pharmaceuticals' potential for growth and performance in the market.
UBS has upgraded Jazz Pharmaceuticals to a Buy rating, raising the price target from $145 to $179, citing confidence in its core business and the Ziihera pipeline's potential. The company boasts a gross profit margin of 92.4% and is considered undervalued, with analysts revising earnings expectations upward for the coming years. Despite some challenges, Jazz continues to perform strongly, particularly in its sleep and oncology segments, and is forecasting sales growth of 5% for 2025.
UBS has raised its price target on Flutter Entertainment to $340 from $335 while maintaining a Buy rating. Flutter, a leading betting company in Ireland, generates 55.8% of its net sales from sports betting and 39.2% from non-sports betting, with significant revenue coming from the U.S. (37.2%) and the U.K. (23.2%).
UBS has raised its price target for Flutter Entertainment to $340, up from the previous target of $335. This adjustment reflects the firm's updated outlook on the company's performance in the market.
UK banks experienced over 803 hours of IT outages in the past two years, affecting millions of customers. Barclays alone anticipates compensating between £5 million and £12.5 million for recent disruptions, highlighting the significant impact of these failures on individuals, especially during critical times like payday. The Treasury Committee emphasizes the need for banks to improve their response to such incidents and keep customers informed.
UBS analyst Ben Shelley has reaffirmed a Buy rating for Flutter Entertainment, maintaining a price target of $335, despite an 11% stock decline from its February high. The company reported strong guidance for U.S. operations, projecting significant revenue growth and an ambitious EBITDA target of $2.4 billion by 2027. Flutter's recent earnings surpassed expectations, driven by robust performance in its U.S. segment, particularly with FanDuel, which commands a 43% market share in gross gaming revenue.
UBS has reiterated a Buy rating for Flutter Entertainment shares, maintaining a price target of $335, despite an 11% decline from its February high. The company reported strong fourth-quarter results, with adjusted earnings per share of $2.94, significantly surpassing expectations, and projected robust growth in its US operations, particularly through FanDuel. Flutter anticipates revenue of $15.48 billion to $16.38 billion for 2025, driven by a 19.9% revenue growth over the past year and a strong market position.
Alkermes has been upgraded to a Neutral rating from Sell by UBS, indicating a shift in the firm's outlook on the company's stock. This change reflects a more favorable assessment of Alkermes' potential in the market.
IRL
Country
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs upgrades jazz pharmaceuticals outlook to buy with significant price target increase
01:04 08.03.2025
flutter entertainment stock forecast raised by analysts amid market fluctuations
17:03 07.03.2025
jazz pharmaceuticals receives buy rating upgrade from ubs
12:56 07.03.2025
ubs upgrades jazz pharmaceuticals to buy with price target raised to 179 dollars
11:51 07.03.2025
ubs raises flutter entertainment price target to 340 maintains buy rating
16:03 06.03.2025
UBS raises Flutter Entertainment price target to 340 from 335
13:21 06.03.2025
UK banks face significant IT outages impacting millions of customers
09:51 06.03.2025
ubs maintains buy rating for flutter entertainment with strong guidance and growth
United States Dollar
Flutter Entertainment plc
GBR
ITA
AUS
USA
IRL
Ben Shelley
Peter Jackson
Show more
07:06 05.03.2025
ubs maintains buy rating for flutter entertainment with strong us growth forecast
United States Dollar
Flutter Entertainment plc
GBR
ITA
AUS
USA
IRL
Ben Shelley
Peter Jackson
Show more
07:02 05.03.2025
Alkermes receives Neutral rating upgrade from Sell by UBS
13:12 04.03.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Central Bank Actions
GDP Growth & Recession Forecasts
CEO Changes
Global Trade Developments
Industry Mergers & Acquisitions
Financial Scams and Security
Market Analysis and Predictions
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Domestic Politics
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Credit Suisse Strategic Income I
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Swiss Re AG
Beazley plc
UBS AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Canadian Dollar
Australian Dollar
United Arab Emirates Dirham
Saudi Riyal
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Indonesian Rupiah
South Korean Won
Malaysian Ringgit
Vietnamese Đồng
People: